VALN - Valneva chikungunya vaccine to go through accelerated review in Europe
2023-11-27 04:41:15 ET
More on Valneva
- Valneva: Q3 Earnings, Vaccine Valiance, Outshining Moderna
- Valneva SE (VALN) Q3 2023 Earnings Call Transcript
- Valneva's Vaccination Valor: A Buy Rating Justified
- FDA approves Valneva's world-first chikungunya vaccine
- Valneva reports 9M results
For further details see:
Valneva chikungunya vaccine to go through accelerated review in Europe